Cytoskeleton

AB8939 is a potent microtubule protein polymerization inhibitor that exhibits significant anti-tumor activity, with an IC50 of less than 10 nM against tumor cell proliferation. This compound effectively circumvents resistance mechanisms associated with P-glycoprotein and myeloperoxidase. AB8939 also induces G2/M phase cell cycle arrest and triggers apoptosis in affected cells, making it a valuable tool for cancer research and therapeutic development.

Sabizabulin hydrochloride is a potent microtubule inhibitor that interacts specifically with the colchicine binding site on tubulin. This compound has demonstrated significant antitumor activity, exhibiting an average IC50 of 5.2 nM in melanoma and prostate cancer cell lines. Its pharmacological profile indicates a low risk of adverse effects, making it a promising candidate for research in cancer therapeutics.

Tubulin inhibitor 35 is a dual inhibitor targeting tubulin polymerization and topoisomerase I, with an IC50 of approximately 5.69 μM and 50 μM, respectively. This compound demonstrates significant anti-tumor activity, effectively inhibiting the migration and invasion of MGC-803 and RKO cell lines, and inducing apoptosis by arresting the cell cycle at the G2/M phase. With potent efficacy against gastrointestinal tumors, Tubulin inhibitor 35 exhibits an IC50 of 0.09 μM in MGC-803 and 0.2 μM in RKO cell lines, making it a valuable reagent for cancer research applications.

Tubulin polymerization-IN-31 is a tubulin polymerization inhibitor with an IC50 of 3.64 μM. This compound interferes with microtubule dynamics, leading to the induction of apoptosis in cancer cells. Its antitumor activity makes it a valuable tool for investigating cancer biology and developing therapeutic strategies targeting microtubule-dependent processes.

DAT-230 is a microtubule inhibitor that induces cell apoptosis by promoting microtubule de-polymerization and causing G2/M phase cell cycle arrest. This compound effectively inhibits cell growth both in vitro and in vivo, making it valuable for studies on cancer cell proliferation and the mechanisms of action related to microtubule dynamics. Researchers can utilize DAT-230 to explore therapeutic strategies targeting microtubule function in various cellular contexts.

Tubulin-IN-51 is a potent tubulin inhibitor with an IC50 of 31 nM, demonstrating oral bioavailability. It promotes tubulin polymerization in vitro and uniquely does not compete with Paclitaxel for binding sites, while inhibiting the interaction of Vinblastine with tubulin. This compound effectively downregulates the G1 phase of the cell cycle and induces apoptosis, leading to significant tumor growth inhibition in various nude mouse xenograft models. Tubulin-IN-51 is valuable for research in cancer biology and therapeutic applications targeting microtubule dynamics.

Tubulin Inhibitor 13 is a potent compound that targets tubulin polymerization, exhibiting an IC50 value of 16.1 μM. It effectively inhibits cancer cell migration and invasion, promotes apoptosis, and displays significant anticancer activity. Its mechanisms make it a valuable tool for research into cancer biology and potential therapeutic applications.

Tubulin Inhibitor 32 is a potent agent targeting tubulin, demonstrating significant anti-proliferative effects through the inhibition of microtubule polymerization. This compound induces apoptosis and causes cell cycle arrest at the G2/M phase, making it a valuable tool for cancer research. Its anti-tumor activity further supports its potential applications in studying cancer cell dynamics and therapeutic resistance.

Tubulin inhibitor 43 is a potent β-microtubulin inhibitor that exhibits significant antitumor activity. By impeding β-microtubulin function, it effectively disrupts cancer cell proliferation and growth, ultimately leading to the induction of apoptosis. This compound is valuable for research applications focused on cancer biology and therapeutic development.

APD-94 is a dual inhibitor that targets both tubulin and Bmi-1, disrupting normal tubulin polymerization. This compound downregulates Bmi-1 expression, leading to cell cycle arrest at the G2/M phase and subsequent induction of apoptosis in cancer cells. APD-94 effectively inhibits cancer cell proliferation and demonstrates growth repression of HT29 cell xenografts in NOD/SCID mice. Its applications are particularly relevant in the study of colorectal cancer.

Tubulin polymerization-IN-22 is a potent inhibitor of tubulin polymerization, exhibiting an IC50 of 8.1 μM. This compound effectively arrests the cell cycle at the G2/M phase and induces apoptosis in various cell lines. Its utility in research applications includes studying cell cycle regulation and the mechanisms of apoptosis.

N-Deacetyl-N-formylcolchicine is a potent inhibitor targeting the colchicine-binding site of tubulin. This compound demonstrates significant antiproliferative activity across multiple cancer cell lines, with IC50 values ranging from 32.61 to 100.28 nM. By inhibiting microtubule polymerization, N-Deacetyl-N-formylcolchicine effectively blocks cell division, induces apoptosis in cancer cells, and suppresses cellular migration. Its application is particularly relevant in the research of lung cancer and various solid tumors.

Tubulin polymerization-IN-43 is a potent tubulin polymerization inhibitor that effectively disrupts cellular microtubule networks by binding to the Colchicine site. This compound promotes cell cycle arrest at the G2/M phase and induces apoptosis in leukemia cells, thereby demonstrating significant anti-cancer activity. Additionally, Tubulin polymerization-IN-43 has been shown to inhibit angiogenesis, making it a valuable tool for cancer research and therapeutic development.

S-72 is a potent tubulin inhibitor that disrupts tubulin polymerization, leading to mitotic phase cell cycle arrest and apoptosis in cancer cells. Additionally, S-72 has been shown to suppress STAT3 signaling, making it a valuable tool for investigating mechanisms of cancer cell proliferation and survival. Its ability to target both microtubule dynamics and critical signaling pathways highlights its potential in cancer research.

Tubulin polymerization-IN-26 is a potent inhibitor of microtubulin polymerization, specifically targeting the colchicine binding site with an IC50 value of 4.64 μM. This compound exhibits cytotoxic effects by inducing apoptosis and impeding cellular migration and metastasis. It serves as a valuable tool for research applications focused on lung cancer and related studies in tumor dynamics.

IMB5046 is a potent microtubule inhibitor that disrupts microtubule dynamics, leading to cell cycle arrest at the G2/M phase and subsequent apoptosis. This compound exhibits significant anti-tumor activity, making it a valuable reagent for cancer research and therapeutic studies focused on cell proliferation and apoptosis mechanisms.

αβ-Tubulin-IN-1 is a powerful inhibitor targeting αβ-Tubulin. This compound effectively induces cell cycle arrest at the G2/M phase and promotes efficient apoptosis in cancer cells. Additionally, αβ-Tubulin-IN-1 inhibits tumor cell migration and metastasis, demonstrating significant antitumor efficacy in a dose-dependent manner. It serves as a valuable tool for research into cell cycle regulation and cancer therapeutics.

PF-3758309 hydrochloride is a potent and reversible ATP-competitive inhibitor targeting PAK4, with a Kd of 2.7 nM and a Ki of 18.7 nM. This compound is effective in inhibiting anchorage-independent growth and inducing apoptosis, while also promoting cytoskeletal remodeling and suppressing cellular proliferation. PF-3758309 hydrochloride is valuable in research applications aimed at understanding PAK4's role in cancer and other diseases associated with dysregulated cell growth.

DPP-21 is a potent inhibitor of tubulin polymerization, with an IC50 value of 2.4 μM. This compound exhibits significant anti-proliferative effects in various cancer cell lines, including IC50 values of 0.38 nM in HCT116, 11.69 nM in B16, 5.37 nM in HeLa, 9.53 nM in MCF7, 8.94 nM in H23, and 9.37 nM in HepG2. DPP-21 effectively arrests the cell cycle at the G2/M phase, leading to increased apoptosis in tumor cells, as demonstrated by a decrease in Bcl-2 levels and an upregulation of the pro-apoptotic protein Bax.

3-(3-Phenoxybenzyl)amino-β-carboline is a potent inhibitor of tubulin, specifically targeting αβ-tubulin heterodimers. This compound has been shown to induce G2/M phase cell cycle arrest and subsequent apoptosis in cancer cells. Its significant anticancer activity makes it a valuable tool for research applications aimed at understanding tumor biology and developing novel therapeutic strategies.

HI5 is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO) and tubulin, demonstrating an IC50 of 70 nM in HeLa cells. It effectively reduces kynurenine production, thereby promoting T cell activation and proliferation. Additionally, HI5 interferes with tubulin polymerization and migration, induces G2/M phase cell cycle arrest, and triggers apoptosis through a mitochondrial-dependent pathway, leading to increased reactive oxidative stress. HI5 is suitable for research in anticancer applications.

Tubulin polymerization-IN-24 is a potent inhibitor of tubulin polymerization. This compound effectively inhibits the proliferation of MCF-7 breast cancer cells, inducing apoptosis and causing cell cycle arrest at the G2/M phase. Additionally, Tubulin polymerization-IN-24 enhances the rate of GTP hydrolysis while inhibiting microtubule assembly, making it a valuable tool for research into cancer biology and cellular dynamics.

Tubulin polymerization-IN-86 is a potent inhibitor of tubulin polymerization that targets the colchicine binding sites on microtubulin, effectively disrupting the microtubule cytoskeleton. This compound demonstrates significant anti-proliferative activity against various cancer cell lines and induces mechanisms such as cell cycle arrest and apoptosis. Additionally, it inhibits cell migration and invasion, contributing to reduced long-term survival of cancer cells. Tubulin polymerization-IN-86 also exhibits efficacy in inhibiting tumor growth in murine models, making it a valuable tool for research in melanoma and related studies.

Tubulin inhibitor 42 (Compound 14b) primarily targets β-microtubulin, exhibiting dose-dependent inhibition with an IC50 of 3.5 µM. This compound disrupts microtubule dynamics, leading to cancer cell cycle arrest in the G2/M phase and triggering apoptosis. Additionally, Tubulin inhibitor 42 demonstrates significant inhibitory effects on angiogenesis, both in vitro and in vivo, ultimately suppressing vascularization and tumor progression.

SKLB0565 is a potent tubulin inhibitor that demonstrates significant anti-proliferative effects in colorectal carcinoma (CRC) cell lines, with IC50 values ranging from 0.012 μM to 0.081 μM. This compound induces G2/M phase cell cycle arrest and triggers mitochondria-mediated intrinsic apoptosis. Additionally, SKLB0565 effectively inhibits cell migration and disrupts tube formation in human umbilical vein endothelial cells (HUVECs), making it a valuable tool for cancer research and the study of tumor angiogenesis.

Microtubulin-IN-1 is a selective inhibitor of microtubulin that targets the colchicine-binding site, leading to disruption of microtubule integrity and upregulation of p53. It demonstrates significant antiproliferative activity across various cancer cell lines, with IC50 values of 2.4 nM for NCI-H460, 1.6 nM for BxPC-3, and 2.07 nM for HT-29. Microtubulin-IN-1 effectively induces cell cycle arrest at the G2/M phase and promotes apoptosis in NCI-H460 cells, making it a valuable tool for cancer research.

Tubulin polymerization-IN-6 is a potent tubulin polymerization inhibitor with an IC50 of 1.09 μM. This compound effectively impairs cell migration and tube formation, playing a significant role in anti-angiogenesis. In vivo studies demonstrate that Tubulin polymerization-IN-6 substantially inhibits tumor growth in HT29 xenograft models using Balb/c nude mice, making it a valuable reagent for cancer research.

VEGFR-2-IN-22 is a dual inhibitor targeting VEGFR-2 and β-tubulin polymerization, demonstrating an IC50 of 19.82 nM against VEGFR-2. This compound promotes apoptosis, making it a valuable tool for studying angiogenesis and cancer biology. Its mechanism of action provides insights into vascular endothelial growth factor pathways and their role in tumor progression.

Tubulin polymerization-IN-17 is a potent inhibitor of tubulin polymerization, effectively disrupting microtubule dynamics. This compound induces depolymerization of tubulin, leading to apoptosis in cancer cells and inhibiting their migratory capabilities. Tubulin polymerization-IN-17 is valuable for research focused on cancer biology and therapies targeting microtubule dynamics.

Tubulin polymerization-IN-84 is a selective inhibitor of tubulin polymerization that targets the colchicine-binding site, exhibiting an IC50 of 10.9 μM. This compound demonstrates significant antiproliferative effects against various cancer cell lines, including Jurkat, B16-F10, HCT116, and MDA-MB-231, with IC50 values of 60 nM, 380 nM, 138 nM, and 1.054 μM, respectively. Tubulin polymerization-IN-84 induces G2/M-phase arrest and promotes apoptosis in B16-F10 cells, while also suppressing tumor growth in a B16-F10 melanoma model. Additionally, it enhances anti-tumor immunity in conjunction with PD-L1 monoclonal antibodies, making it a valuable reagent for research in T-cell acute lymphoblastic leukemia, melanoma, colon cancer, and breast cancer studies.

Antitumor agent-68 is a potent tubulin inhibitor that demonstrates significant anticancer activity, with IC50 values of 3.6 μM and 3.8 μM against HeLa and MCF-7 cancer cell lines, respectively. This compound exhibits strong reactive oxygen species (ROS) and DPPH radical scavenging activity in a dose-dependent manner, making it relevant for oxidative stress research. Antitumor agent-68 also features an alkyne group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, facilitating advancements in chemical biology applications.